Pramipexole: Effective for Fibromyalgia?

In a recently conducted double-blind study by Drs. Andrew J Holman and Robin R Myers, pramipexole, a dopamine agonist, demonstrated both safety and efficacy in patients with fibromyalgia. Sixty fibromyalgia patients were treated for 14 weeks with either escalating doses of pramipexole or placebo. Outcome was measured by pain score and a number of secondary measures, including the Fibromyalgia Impact Questionnaire. At 14 weeks, pain scores had dropped 36% in the pramipexole arm and 9% in the placebo arm. Those treated with pramipexole also demonstrated significant improvement in fatigue, function, and global status. This study was published in Arthritis & Rheumatism. http://www3.interscience.wiley.com/cgi-bin/abstract/110575103/ABSTRACT